CClinicalTrials.gg
CompletedNCT03286010Updated Jul 16, 2024

Peer Support for Women With Heart Disease: Women@Heart

An interventional study of Women@Heart Program in Coronary Heart Disease and Women's Health, sponsored by Ottawa Heart Institute Research Corporation. Completed at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Women with heart disease are more likely to die or suffer another cardiac event or stroke within 5 years of an index event compared to men. They are also more likely to suffer depression and report lower quality of life. Cardiac Rehabilitation programs have been designed to address these issues, but most women do not attend. Women indicate they have a greater need to talk about their experiences with heart disease and seek social support to help them cope. Peer support, the assistance provided by other women with a similar illness experience, may be one way to enhance social support for women with heart disease and help them improve their psychosocial well-being. The Investigators have developed a peer support program called Women@Heart (W@H). The program is led by trained peer leaders (women who themselves have made a successful recovery from a heart event). A pilot test of the program showed promising results. The Investigators now need to conduct a more rigorous evaluation of the program.

The main objective of this project is to determine if the W@H program helps women to improve their psychosocial well-being compared to being on a waiting list to participate in the program. It will also examine the effect of the program on: health behaviours (tobacco smoking, physical activity, sedentary behaviour, fruit and vegetable consumption, and medication adherence); coronary risk factors; and clinical outcomes (re-hospitalization, health care system use, death).

02

Conditions studied

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Women who have been hospitalized at UOHI in the past year with stable CHD, including: AMI; stable angina with corroborating evidence of CHD; recent CABG; or percutaneous coronary intervention (to allow examination of mechanisms linking the intervention and psychosocial well-being with health and healthcare outcomes);
  2. Women ≥ 18 years of age (the age of consent in Ontario);
  3. Women able to read and understand English or French;
  4. Women who reside in Ontario and are eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
  5. Women available to participate over the next 6 months (the intervention and data collection takes place over this time frame -- reducing the probability of missing data);
  6. Women able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Women who have been hospitalized primarily for valve replacement or repair, HF, pulmonary hypertension, endocarditis or pericarditis (to reduce heterogeneity and avoid confounding when examining mechanisms linking the intervention and psychosocial well-being with health and healthcare outcomes);
  2. Women who, in the opinion of the UOHI clinical psychologist, manifest psychiatric illness or cognitive impairment that would preclude participation in W@H (i.e. they are unable to benefit from the intervention, to prevent disruption of other participants).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Intervention

    Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).

    Behavioral: Women@Heart Program

  • No intervention
    Control

    Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.

Interventions

  • BehavioralWomen@Heart Program

    The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.

05

What researchers measure

Primary outcomes

  1. Psychosocial well-being as measured by a total composite score

    The composite score will combine data from seven measures (ESSI, BCI, BAI, BDI2, MCS, HeartQol and PSS)

    Time frame: Baseline to week 26 follow up

Secondary outcomes

  1. Smoking Status

    Measured by self report and carbon monoxide breath test

    Time frame: Baseline to week 26 follow up

  2. Fruit/Vegetable consumption

    Measured by two questions from the Ontario Health Study that assess typical daily servings of fruits and vegetables.

    Time frame: Baseline to week 26 follow up

  3. Menstrual Status

    Measured through self reported menstrual status (i.e., pre, peri or post-menopausal)

    Time frame: Baseline to week 26 follow up

  4. Gender Role Identity

    The BEM Sex Role Inventory will be used to assess participants' feelings towards their own gender role identities (masculine, feminine, androgynous and undifferentiated).

    Time frame: Baseline to week 26 follow up

  5. Physical Activity

    Measured through self reported physical activity

    Time frame: Baseline to week 26 follow up

  6. Salt Consumption

    Assessed using 1 question from the Canadian Community Health Survey (2015) that assess weekly intake of salty foods.

    Time frame: Baseline to week 26 follow up

  7. Medication Adherence

    Assessed through two questions asking whether or not participants ever forget to take their medication and if they ever stop taking their medication (if so why).

    Time frame: Baseline to week 26 follow up

06

Study locations

1 site
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y4M2, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03286010
Lead sponsor
Ottawa Heart Institute Research Corporation
Responsible party
Sponsor
First posted
Sep 18, 2017
Start date
Jan 1, 2018
Primary completion
Jun 17, 2024
Completion
Jun 17, 2024
Last update
Jul 16, 2024

Study contacts

Kerri Mullen
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion